Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update.

Literature DB >> 26111906

Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update.

Gianluigi Ardissino¹, Ilaria Possenti², Francesca Tel², Sara Testa², Stefania Salardi², Vito Ladisa².

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2015 PMID： 26111906 DOI： 10.1053/j.ajkd.2015.04.010

Source DB: PubMed Journal: Am J Kidney Dis ISSN： 0272-6386 Impact factor: 8.860

Keyword Cloud
Cited

× No keyword cloud information.

39 in total

1. Eculizumab and aHUS: to stop or not.

Authors: Robert A Brodsky
Journal: Blood Date: 2021-05-06 Impact factor: 22.113

2. Eculizumab cessation in atypical hemolytic uremic syndrome.

Authors: Samuel A Merrill; Zachary D Brittingham; Xuan Yuan; Alison R Moliterno; C John Sperati; Robert A Brodsky
Journal: Blood Date: 2017-05-01 Impact factor: 22.113

Review 3. Atypical hemolytic uremic syndrome.

Authors: Vahid Afshar-Kharghan
Journal: Hematology Am Soc Hematol Educ Program Date: 2016-12-02

4. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way.

Authors: Gema Ariceta
Journal: Pediatr Nephrol Date: 2019-01-28 Impact factor: 3.714

5. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.

Authors: Fadi Fakhouri; Marc Fila; François Provôt; Yahsou Delmas; Christelle Barbet; Valérie Châtelet; Cédric Rafat; Mathilde Cailliez; Julien Hogan; Aude Servais; Alexandre Karras; Raifah Makdassi; Feriell Louillet; Jean-Philippe Coindre; Eric Rondeau; Chantal Loirat; Véronique Frémeaux-Bacchi
Journal: Clin J Am Soc Nephrol Date: 2016-10-31 Impact factor: 8.237

6. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update.

Authors: Gianluigi Ardissino; Francesca Tel; Martina Sgarbanti; Donata Cresseri; Antenore Giussani; Samantha Griffini; Elena Grovetto; Ilaria Possenti; Michela Perrone; Sara Testa; Fabio Paglialonga; Piergiorgio Messa; Massimo Cugno
Journal: Pediatr Nephrol Date: 2017-10-18 Impact factor: 3.714

Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update.

1. Eculizumab and aHUS: to stop or not.

2. Eculizumab cessation in atypical hemolytic uremic syndrome.

Review 3. Atypical hemolytic uremic syndrome.

4. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way.

5. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.

6. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update.

Review 7. Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS.

8. The Benefits of Complement Measurements for the Clinical Practice.

Review 9. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.

Review 10. Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era.